Strategic Partnerships Leverage CureMetrix's FDA-cleared cmAngio and BAC detection to secure pilots with imaging centers and hospital networks seeking to extend cardiovascular risk assessment through mammography; emphasize existing collaborations with Cascaid Health, Rezolut Imaging, and Onsite Mammography to demonstrate credibility and speed to value; propose co-marketed pilots integrated within current PACS and 3D screening workflows, and highlight ISO 13485 certification to reassure procurement teams.

Workflow Efficiency Position CureMetrix as a high-accuracy, low-disruption adjunct that reduces recalls and radiologist workload while fitting into existing workflows; cite a large training image dataset and worldwide collaborations as proof of robust performance; emphasize cloud-based deployment and analytics to deliver measurable ROI; offer time-bound pilots to quantify cost savings.

Cardio Health Expansion Expand addressable market by marketing BAC-based cardiovascular risk assessment as part of preventive care for women; promote partnership with Cascaid to translate detection into actionable next steps; target cardiology, primary care, and women's health clinics; cross-sell with 3D imaging services to provide richer patient insights.

Regulatory Credibility Regulatory and quality credibility supports enterprise procurement; FDA clearance for cmAngio and ISO 13485 certification signal reliability for hospital and imaging groups seeking compliant AI solutions; highlight existing adopters to illustrate traction and reduce perceived risk in contracting.

Data-Driven Growth Capitalize on a data-rich platform built from millions of clinical images and broad clinical collaborations to support broader deployments and multi-site rollouts; leverage AWS hosting and Looker analytics to enable scalable, secure deployments and evidence-based selling.